Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study

1Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: challenges and future directions. Intensive Care Med 2020;46(11):2001-14.Logan C Martin-Loeches I Bicanic T Invasive candidiasis in critical care: challenges and future directions Intensive Care Med 202046112001 1410.1007/s00134-020-06240-x32990778Search in Google Scholar

2Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 2014;40(9):1303-12.Lortholary O Renaudat C Sitbon K Madec Y Denoeud-Ndam L Wolff M et al Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010) Intensive Care Med 20144091303 1210.1007/s00134-014-3408-3414724725097069Search in Google Scholar

3Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1-50.Pappas PG Kauffman CA Andes DR Clancy CJ Marr KA Ostrosky-Zeichner L et al Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America Clin Infect Dis 2016624e1 5010.1093/cid/civ933472538526679628Search in Google Scholar

4Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012;18(Suppl 7):19-37.Cornely OA Bassetti M Calandra T Garbino J Kullberg BJ Lortholary O et al ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients Clin Microbiol Infect 201218Suppl 719 3710.1111/1469-0691.1203923137135Search in Google Scholar

5Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009;37(5):1612-8.Leroy O Gangneux JP Montravers P Mira JP Gouin F Sollet JP et al Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006) Crit Care Med 20093751612 810.1097/CCM.0b013e31819efac019325476Search in Google Scholar

6Thomas-Rüddel DO, Schlattmann P, Pletz M, Kurzai O, Bloos F. Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis. Chest 2022;161(2):345-55.Thomas-Rüddel DO Schlattmann P Pletz M Kurzai O Bloos F Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis Chest 20221612345 5510.1016/j.chest.2021.08.081894162234673022Search in Google Scholar

7Bruyère R, Quenot JP, Prin S, Dalle F, Vigneron C, Aho S, et al. Empirical antifungal therapy with an echinocandin in criticallyill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU. BMC Infect Dis 2014;14:385.Bruyère R Quenot JP Prin S Dalle F Vigneron C Aho S et al Empirical antifungal therapy with an echinocandin in criticallyill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU BMC Infect Dis 20141438510.1186/1471-2334-14-385422729625015848Search in Google Scholar

8Ciurea CN, Santini A, Mare AD, Kosovski IB, Toma F, Vintila C, Pintea-Simon IA, Man A. Candida Spp. in Lower Respiratory Tract Secretions - A Ten Years Retrospective Study. J Crit Care Med (Targu Mures) 2021;7(3):217-26.Ciurea CN Santini A Mare AD Kosovski IB Toma F Vintila C Pintea-Simon IA Man A Candida Spp in Lower Respiratory Tract Secretions - A Ten Years Retrospective Study. J Crit Care Med (Targu Mures) 202173217 2610.2478/jccm-2021-0016851938334722925Search in Google Scholar

9Cui N, Wang H, Su L, Qiu H, Li R, Liu D, et al. Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study. BMC Infect Dis 2017;17(1):93.Cui N Wang H Su L Qiu H Li R Liu D et al Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study BMC Infect Dis 20171719310.1186/s12879-017-2207-1526013328114898Search in Google Scholar

10Nucci M, Nouér SA, Esteves P, Guimarães T, Breda G, de Miranda BG, et al. Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucan. J Antimicrob Chemother 2016;71:2628-33.Nucci M Nouér SA Esteves P Guimarães T Breda G de Miranda BG et al Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucan J Antimicrob Chemother 2016712628 3310.1093/jac/dkw18827287231Search in Google Scholar

11Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5.Morrell M Fraser VJ Kollef MH Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality Antimicrob Agents Chemother 2005493640 510.1128/AAC.49.9.3640-3645.2005Search in Google Scholar

12Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother 2010;65:1765-70.Hsu DI Nguyen M Nguyen L Law A Wong-Beringer A A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients J Antimicrob Chemother 2010651765 7010.1093/jac/dkq216Search in Google Scholar

13Falces-Romero I, Romero-Gómez MP, Moreno-Ramos F, Mingorance J, García-Rodríguez J, Cendejas-Bueno E. Epidemiology of bloodstream Candida species in a Spanish tertiary care hospital as a guide for implementation of T2MR (T2CANDIDA®) for rapid diagnosis of candidemia. Med Mycol 2021;59(4):350-4.Falces-Romero I Romero-Gómez MP Moreno-Ramos F Mingorance J García-Rodríguez J Cendejas-Bueno E Epidemiology of bloodstream Candida species in a Spanish tertiary care hospital as a guide for implementation of T2MR (T2CANDIDA®) for rapid diagnosis of candidemia Med Mycol 2021594350 410.1093/mmy/myaa056Search in Google Scholar

14Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25–31.Garey KW Rege M Pai MP Mingo DE Suda KJ Turpin RS et al Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin Infect Dis 20064325 3110.1086/504810Search in Google Scholar

15Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003;3:772–85.Eggimann P Garbino J Pittet D Management of Candida species infections in critically ill patients Lancet Infect Dis 20033772 8510.1016/S1473-3099(03)00831-4Search in Google Scholar

16Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161–89.Pappas PG Rex JH Sobel JD Filler SG Dismukes WE Walsh TJ et al Guidelines for treatment of candidiasis Clin Infect Dis 200438161 8910.1086/38079614699449Search in Google Scholar

17Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;5:627–30.Trick WE Fridkin SK Edwards JR Hajjeh RA Gaynes RP; National Nosocomial Infections Surveillance System Hospitals Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999 Clin Infect Dis 20025627 3010.1086/34230012173140Search in Google Scholar

18Tortorano AM, Caspani L, Rigoni AL, Biraghi E, Sicignano A, Viviani MA. Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect 2004;57:8–13.Tortorano AM Caspani L Rigoni AL Biraghi E Sicignano A Viviani MA Candidosis in the intensive care unit: a 20-year survey J Hosp Infect 2004578 1310.1016/j.jhin.2004.01.01715142710Search in Google Scholar

19Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298–302.Diekema DJ Messer SA Brueggemann AB Coffman SL Doern GV Herwaldt LA et al Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study J Clin Microbiol 2002401298 30210.1128/JCM.40.4.1298-1302.200214038011923348Search in Google Scholar

20Hobson RP. The global epidemiology of invasive Candida infections—is the tide turning? J Hosp Infect 2003;55:159– 68;quiz 233.Hobson RP The global epidemiology of invasive Candida infections—is the tide turning? J Hosp Infect 200355159–68quiz 23310.1016/j.jhin.2003.08.01214572481Search in Google Scholar

21Davis SL, Vazquez. Anidulafungin: an evidence-based review of its use in invasive fungal infections. Core Evid 2007;2:241–9.Davis SL Vazquez Anidulafungin: an evidence-based review of its use in invasive fungal infections Core Evid 20072241 9Search in Google Scholar

22Hanson KE, Pfeifer CD, Lease ED, Balch AH, Zaas AK, Perfect JR, et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012;7:e42282.Hanson KE Pfeifer CD Lease ED Balch AH Zaas AK Perfect JR et al β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study PLoS One 20127e4228210.1371/journal.pone.0042282341284822879929Search in Google Scholar

23Ket DH, Azoulay E, Echeverria PM, Vincent JL. Extended prevalence of infection in ICU study (EPIC II) group of investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011;39:665–70.Ket DH Azoulay E Echeverria PM Vincent JL Extended prevalence of infection in ICU study (EPIC II) group of investigators Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 201139665 7010.1097/CCM.0b013e318206c1ca21169817Search in Google Scholar

24Pfaller MA1, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254–9.Pfaller MA1 Diekema DJ Jones RN Sader HS Fluit AC Hollis RJ et al International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001393254 910.1128/JCM.39.9.3254-3259.20018832711526159Search in Google Scholar

25Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 2011;49:665-70.Avni T Leibovici L Paul M PCR diagnosis of invasive candidiasis: systematic review and meta-analysis J Clin Microbiol 201149665 7010.1128/JCM.01602-10304351821106797Search in Google Scholar

26Moghnieh R, Kanafani ZA, Kanj SS. Antifungal use in intensive care units: another uncertainty that highlights the need for precision medicine. J Thorac Dis 2016;8:E1672-5.Moghnieh R Kanafani ZA Kanj SS Antifungal use in intensive care units: another uncertainty that highlights the need for precision medicine J Thorac Dis 20168E1672 510.21037/jtd.2016.12.97522726728149610Search in Google Scholar

27Lamagni TL, Evans BG, Shigematsu M, Johnson EM. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect 2001;126:397-414.Lamagni TL Evans BG Shigematsu M Johnson EM Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9) Epidemiol Infect 2001126397 41410.1017/S0950268801005507286970811467797Search in Google Scholar

28Flückiger U, Marchetti O, Bille J, Eggimann P, Zimmerli S, Imhof A, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006;136:447-63.Flückiger U Marchetti O Bille J Eggimann P Zimmerli S Imhof A et al Treatment options of invasive fungal infections in adults Swiss Med Wkly 2006136447 63Search in Google Scholar

29Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009;48:1695–703.Horn DL Neofytos D Anaissie EJ Fishman JA Steinbach WJ Olyaei AJ et al Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry Clin Infect Dis 2009481695 70310.1086/59903919441981Search in Google Scholar

30Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008;149:83-90.Schuster MG Edwards JE Jr Sobel JD Darouiche RO Karchmer AW Hadley S et al Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial Ann Intern Med 200814983 9010.7326/0003-4819-149-2-200807150-0000418626047Search in Google Scholar

31Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Bets R, Barron MA, et al. MSG- 01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care seting. Clin Infect Dis 2014;58:121926.Ostrosky-Zeichner L Shoham S Vazquez J Reboli A Bets R Barron MA et al MSG- 01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care seting Clin Infect Dis 20145812192610.1093/cid/ciu07424550378Search in Google Scholar

32Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M, Souweine B, et al. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: The EMPIRICUS randomized clinical trial. JAMA 2016;316:1555-64.Timsit JF Azoulay E Schwebel C Charles PE Cornet M Souweine B et al Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: The EMPIRICUS randomized clinical trial JAMA 20163161555 6410.1001/jama.2016.1465527706483Search in Google Scholar

33Sabol K, Gumbo T. Anidulafungin in the treatment of invasive fungal infections. Ther Clin Risk Manag 2008;4:71-8.Sabol K Gumbo T Anidulafungin in the treatment of invasive fungal infections Ther Clin Risk Manag 2008471 810.2147/TCRM.S882Search in Google Scholar

34Concia E, Azzini AM, Conti M. Epidemiology, incidence and risk factors for invasive candidiasis in high‐risk patients. Drugs 2009;69:5-14.Concia E Azzini AM Conti M Epidemiology, incidence and risk factors for invasive candidiasis in high‐risk patients Drugs 2009695 1410.2165/11315500-000000000-0000019877728Search in Google Scholar

35Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-163.Pfaller MA Diekema DJ Epidemiology of invasive candidiasis: a persistent public health problem Clin Microbiol Rev 200720133 16310.1128/CMR.00029-06179763717223626Search in Google Scholar

36López-Cortés LE, Almirante B, Cuenca-Estrella M, Garnacho-Montero J, Padilla B, Puig-Asensio M, et al. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. Clin Microbiol Infect 2016;22:733.e1-8.López-Cortés LE Almirante B Cuenca-Estrella M Garnacho-Montero J Padilla B Puig-Asensio M et al Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort Clin Microbiol Infect 201622733e1-810.1016/j.cmi.2016.05.00827189197Search in Google Scholar

37Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5‐year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk difusion testing. J Clin Microbiol 2005;43:5848-5859.Pfaller MA Diekema DJ Rinaldi MG Barnes R Hu B Veselov AV et al Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5‐year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk difusion testing J Clin Microbiol 2005435848 585910.1128/JCM.43.12.5848-5859.2005131720716333066Search in Google Scholar

38Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012,54:1110-22.Andes DR Safdar N Baddley JW Playford G Reboli AC Rex JH et al Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials Clin Infect Dis 2012541110 2210.1093/cid/cis02122412055Search in Google Scholar

39Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005;43:5425-7.Pfaller MA Boyken L Hollis RJ Messer SA Tendolkar S Diekema DJ In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole J Clin Microbiol 2005435425 710.1128/JCM.43.11.5425-5427.2005128782316272464Search in Google Scholar

40Morace G, Borghi E, Iata R, Montagna MT. Anidulafungin, a new echinocandin: in vitro activity. Drugs 2009;69:91-94.Morace G Borghi E Iata R Montagna MT Anidulafungin, a new echinocandin: in vitro activity Drugs 20096991 9410.2165/11315560-000000000-0000019877740Search in Google Scholar

41Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009;47:3170-7.Diekema DJ Messer SA Boyken LB Hollis RJ Kroeger J Tendolkar S et al In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods J Clin Microbiol 2009473170 710.1128/JCM.00942-09275693119710283Search in Google Scholar

42Cuenca‐Estrella M, Mellado E, Díaz‐Guerra TM, Monzón A, Rodríguez‐Tudela JL. Susceptibility of fluconazole‐resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother 2000;46:475-7.Cuenca‐Estrella M Mellado E Díaz‐Guerra TM Monzón A Rodríguez‐Tudela JL Susceptibility of fluconazole‐resistant clinical isolates of Candida spp to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother 200046475 710.1093/jac/46.3.47510980178Search in Google Scholar

43Gil-Alonso S, Quindós G, Cantón E, Eraso E, Jauregizar N. Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity. Rev Iberoam Micol 2019;36(1):24-9.Gil-Alonso S Quindós G Cantón E Eraso E Jauregizar N Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity Rev Iberoam Micol 201936124 910.1016/j.riam.2018.12.00130837186Search in Google Scholar

44Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82.Reboli AC Rotstein C Pappas PG Chapman SW Kett DH Kumar D et al Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 20073562472 8210.1056/NEJMoa06690617568028Search in Google Scholar

45Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44:760-3.Pfaller MA Boyken L Hollis RJ Messer SA Tendolkar S Diekema DJ In vitro susceptibilities of Candida spp to caspofungin: four years of global surveillance. J Clin Microbiol 200644760 310.1128/JCM.44.3.760-763.2006139315416517851Search in Google Scholar

46Ghannoum MA, Chen A, Buhari M, Chandra J, Mukherjee PK, Baxa D, et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 2009;15:274-9.Ghannoum MA Chen A Buhari M Chandra J Mukherjee PK Baxa D et al Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit Clin Microbiol Infect 200915274 910.1111/j.1469-0691.2008.02660.x19210699Search in Google Scholar

47Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 2008;52:2242-3.Jacobson MJ Piper KE Nguyen G Steckelberg JM Patel R In vitro activity of anidulafungin against Candida albicans biofilms Antimicrob Agents Chemother 2008522242 310.1128/AAC.00211-08241579518391031Search in Google Scholar

48Mayr A, Aigner M, Lass-Flörl C. Anidulafungin for the treatment of invasive candidiasis. Clin Microbiol Infect 2011;17:1-12.Mayr A Aigner M Lass-Flörl C Anidulafungin for the treatment of invasive candidiasis Clin Microbiol Infect 2011171 1210.1111/j.1469-0691.2010.03448.x21251147Search in Google Scholar

49Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:1108-11.Ernst EJ Klepser ME Pfaller MA Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans Antimicrob Agents Chemother 2000441108 1110.1128/AAC.44.4.1108-1111.20008982610722525Search in Google Scholar

50Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin‐specific and Candida species‐ related differences. Antimicrob Agents Chemother 2007;51:2257-9.Chamilos G Lewis RE Albert N Kontoyiannis DP Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin‐specific and Candida species‐ related differences Antimicrob Agents Chemother 2007512257 910.1128/AAC.00095-07189135817438060Search in Google Scholar

51Fleischhacker M, Radecke C, Schulz B, Ruhnke M. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 2008;27:127-31.Fleischhacker M Radecke C Schulz B Ruhnke M Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C dubliniensis. Eur J Clin Microbiol Infect Dis 200827127 3110.1007/s10096-007-0411-418057972Search in Google Scholar

52Falcone M, Accarpio F, Venditti M, Vena A, Sibio S, Sammartino P, et al. Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. J Antimicrob Chemother 2010;65:2266-7.Falcone M Accarpio F Venditti M Vena A Sibio S Sammartino P et al Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis J Antimicrob Chemother 2010652266 710.1093/jac/dkq29720682563Search in Google Scholar

53Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 2009;53:5102-7.Crandon JL Banevicius MA Fang AF Crownover PH Knauft RF Pope JS et al Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults Antimicrob Agents Chemother 2009535102 710.1128/AAC.01042-09278633019770284Search in Google Scholar

54Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009;53:2382-91.Petraitis V Petraitiene R Hope WW Meletiadis J Mickiene D Hughes JE et al Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis Antimicrob Agents Chemother 2009532382 9110.1128/AAC.00329-09268722319307368Search in Google Scholar

55Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 2004;38:311-20.Marchetti O Bille J Fluckiger U Eggimann P Ruef C Garbino J et al Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000 Clin Infect Dis 200438311 2010.1086/38063714727199Search in Google Scholar

56Marra AR, Camargo LF, Pignatari AC, Sukiennik T, Behar PR, Medeiros EA, et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J Clin Microbiol 2011;49:1866-71.Marra AR Camargo LF Pignatari AC Sukiennik T Behar PR Medeiros EA et al Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study J Clin Microbiol 2011491866 7110.1128/JCM.00376-11312265321411591Search in Google Scholar

57Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17.Wisplinghoff H Bischoff T Tallent SM Seifert H Wenzel RP Edmond MB Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 200439309 1710.1086/42194615306996Search in Google Scholar

58Cappelletty DM, Jung R. Anidulafungin and its role in candida infections. Infect Drug Resist 2009;2:51-60.Cappelletty DM Jung R Anidulafungin and its role in candida infections Infect Drug Resist 2009251 6010.2147/IDR.S4796310872921694887Search in Google Scholar

59Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2011;15:R253.Kett DH Shorr AF Reboli AC Reisman AL Biswas P Schlamm HT Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis Crit Care 201115R25310.1186/cc10514333480422026929Search in Google Scholar

60Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006;25:419-25.Falagas ME Apostolou KE Pappas VD Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies Eur J Clin Microbiol Infect Dis 200625419 2510.1007/s10096-006-0159-216773391Search in Google Scholar

61Colombo AL, Guimarães T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, et al. Prognostic factors and histor-ical trends in the epidemiology of candidemia in critically ill patients: ananalysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 2014;40:1489–98.Colombo AL Guimarães T Sukienik T Pasqualotto AC Andreotti R Queiroz-Telles F et al Prognostic factors and histor-ical trends in the epidemiology of candidemia in critically ill patients: ananalysis of five multicenter studies sequentially conducted over a 9-year period Intensive Care Med 2014401489 9810.1007/s00134-014-3400-y417683125082359Search in Google Scholar

62Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9.Zaoutis TE Argon J Chu J Berlin JA Walsh TJ Feudtner C The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis Clin Infect Dis 2005411232 910.1086/49692216206095Search in Google Scholar

63Reboli AC, Rotstein C, Kett DH, Maschio M, Cartier S, Chambers R, et al. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics 2011;29:705-17.Reboli AC Rotstein C Kett DH Maschio M Cartier S Chambers R et al Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients Pharmacoeconomics 201129705 1710.2165/11584810-000000000-0000021591820Search in Google Scholar

64Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, et al. Anidulafungin for the treatment of candidaemia/ invasive candidiasis in selected critically ill patients. Clin Microbiol Infect 2012;18:680-7.Ruhnke M Paiva JA Meersseman W Pachl J Grigoras I Sganga G et al Anidulafungin for the treatment of candidaemia/ invasive candidiasis in selected critically ill patients Clin Microbiol Infect 201218680 710.1111/j.1469-0691.2012.03784.x351030622404732Search in Google Scholar